Widespread use of antibiotics in hospitals triggered the emergence of two resistant strains of the Clostridium superbug which has killed thousands of people worldwide over the past two decades, a study has shown.
A genetic analysis of about 300 samples of Clostridium difficile bacteria from around the world found that the global outbreaks were caused by two different strains that had independently acquired resistance to an antibiotic widely used in hospitals.
Scientists traced the evolutionary trees of each strain of C. difficile and found that both originated within a couple of years of each other, one in a hospital in Pittsburg, Pennsylvania, and the other in Montreal, Canada.
International travellers carried the Canadian strain to Britain and the rest of Europe, where it caused a notorious series of outbreaks in UK hospitals between 2003 and 2006, leading to hundreds of patients dying from bowel complications.
"We used advanced DNA sequencing to determine the evolutionary history of this epidemic and the subsequent pattern of global spread," said Miao He of the Wellcome Trust Sanger Institute in Cambridge, which carried out the genetic analysis.
"We found that this outbreak came from two separate epidemic strains or lineages of C. difficile, both emerging from North America over a very short period, and rapidly spread between hospitals around the world."
The study found that both strains of bacteria had undergone the same tiny mutation in a key gene that conferred resistance to the antibiotic fluoroquinolone.
Trevor Lawley, the leader of the study at the Sanger Institute, said: "Until this research, we didn't realise that the same mutation had actually happened twice – independently of one another. It shows that this is not a rare event and can happen again.
"There is a link between acquiring resistance and appearance of these mutations around the world, and the use of the antibiotics."
The study, published in the journal Nature Genetics, said the evolution and persistence of fluoroquinolone-resistant strains of C. difficile was likely to be the result of widespread use of this class of antibiotics in North America in the late 1990s and early 2000s.